RA Capital Management Invests $40M in Bicara Therapeutics Public Offering, Boosting Stake to 11.5%
BCAX has more than doubled off its 52-week low of $7.8.
Summary
RA Capital Management, a major institutional investor, purchased $40 million in common stock and pre-funded warrants in Bicara Therapeutics' recent public offering, increasing its beneficial ownership to 11.5%.
Key Events · Ownership and Investor Activity · BCAX
-
Significant Investment in Public Offering
RA Capital Healthcare Fund, L.P. purchased $40 million worth of common stock and pre-funded warrants in Bicara Therapeutics' public offering on February 26, 2026.
-
Increased Beneficial Ownership
Following the transaction, RA Capital Management and its affiliates now beneficially own 7,279,739 shares, representing 11.5% of Bicara Therapeutics' common stock.
-
Institutional Confidence
This substantial investment by a major institutional holder signals strong confidence in the company's recent capital raise and future prospects.
Analysis · BCAX · Life Sciences
This Schedule 13D/A reveals RA Capital Management's significant participation in Bicara Therapeutics' recent public offering, which closed on February 26, 2026. The $40 million investment, representing over 4% of the company's market capitalization, demonstrates strong institutional confidence in Bicara Therapeutics following its capital raise. While a portion of the investment is in pre-funded warrants with a beneficial ownership blocker, the overall commitment signals a positive outlook from a key investor. This substantial backing could reassure other investors about the company's financial stability and future prospects.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BCAX was trading at $18.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $963.6M. The 52-week trading range was $7.80 to $19.71. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.